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Abstract
Background: The APOA1-C3-A5 gene cluster plays an important role in the regulation of lipids.
Asian Indians have an increased tendency for abnormal lipid levels and high risk of Coronary Artery
Disease (CAD). Therefore, the present study aimed to elucidate the relationship of four single
nucleotide polymorphisms (SNPs) in the Apo11q cluster, namely the -75G>A, +83C>T SNPs in the
APOA1 gene, the Sac1 SNP in the APOC3 gene and the S19W variant in the APOA5 gene to
plasma lipids and CAD in 190 affected sibling pairs (ASPs) belonging to Asian Indian families with a
strong CAD history.
Methods & results: Genotyping and lipid assays were carried out using standard protocols.
Plasma lipids showed a strong heritability (h2 48% – 70%; P < 0.0001). A subset of 77 ASPs with
positive sign of Logarithm of Odds (LOD) score showed significant linkage to CAD trait by multi-
point analysis (LOD score 7.42, P < 0.001) and to Sac1 (LOD score 4.49) and -75G>A (LOD score
2.77) SNPs by single-point analysis (P < 0.001). There was significant proportion of mean allele
sharing (pi) for the Sac1 (pi 0.59), -75G>A (pi 0.56) and +83C>T (pi 0.52) (P < 0.001) SNPs,
respectively. QTL analysis showed suggestive evidence of linkage of the Sac1 SNP to Total
Cholesterol (TC), High Density Lipoprotein-cholesterol (HDL-C) and Apolipoprotein B (ApoB)
with LOD scores of 1.42, 1.72 and 1.19, respectively (P < 0.01). The Sac1 and -75G>A SNPs along
with hypertension showed maximized correlations with TC, TG and Apo B by association analysis.
Conclusion: The APOC3-Sac1 SNP is an important genetic variant that is associated with CAD
through its interaction with plasma lipids and other standard risk factors among Asian Indians.
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Background
Lipids and lipoproteins have been traditionally associated
with high risk of incident coronary artery disease (CAD).
The Apolipoprotein A1-C3-A4-A5 gene cluster on chro-
mosome 11q23 (Apo11q) is among the most well charac-
terized regions of the human genome with reference to
their dynamic association with plasma lipids and lipopro-
teins [1]. The associated haplotypes constitute a highly
informative genetic marker [2]. Extensive interactions
both within and between the genetic variants within this
cluster contribute to the quantitative variation in the
blood lipid phenotypes [3]. The NCBI db SNP Build 116
has established over 182 single nucleotide polymor-
phisms (SNPs) and 4 ins/del variants in this genetically
rich region [4]. A complex pattern of gene expression has
been demonstrated through in vivo studies, wherein the
Apo CIII enhancer acts as a common regulatory element
for the APOA1-C3-A4 genes but not for the APOA5 gene
[5]. Consistent association has been reported from popu-
lation-based studies [6,7] as well as in families with famil-
ial combined hyperlipidemia (FCHL) [8,9] and in
individuals with hypertriglyceridemia [10] across popula-
tions from Americas [9,11], Europe [12,13] and Asia
[14,15]. Both linkage and association analysis on FCHL
families have shown that genetic variation at the Apo11q
gene cluster contribute to the transmission of FCHL phe-
notype across generations in these families [9]. Although
many studies have shown a strong association between
the genetic variants in the Apo11q region with plasma
lipid phenotypes, there have been a few reports to the con-
trary [16,17], implying genetic heterogeneity.
The SNPs in the Apo11q region, particularly the
3238C>G, Sac1 SNP in the 3' untranslated region (UTR)
of the APOC3 gene [18], as well as -1131 C>T promoter
SNP and S19W SNP in exon 2 of the APOA5 gene [10,19]
have been shown to independently and in tandem, regu-
late plasma TG levels [13]. The two promoter SNPs, -
75G>A and +83C>T in the APOA1 gene, have shown
strong association with HDL-C and ApoA1 levels [20].
Although individual genetic variants within the Apo11q
gene cluster have been independently associated with
CAD in some studies [21,22], a majority of them have not
been able to establish such a direct association [23-26].
Association studies have been previously reported on the
Asian Indian population, mostly on healthy adult volun-
teers, to elucidate the role of specific genetic variants in
the APOA1 gene [27], APOC3 gene [28] or the APOA5
gene [29] in regulating plasma lipid levels. Given that this
population has an inherent tendency for dyslipidemia
and associated high risk of CAD [30], the objective of the
present study was to estimate linkage and association
between the 4 genetic variants, namely APOA1, -75G>A
and +83C>T SNPs, the APOC3, Sac1 SNP and the APOA5,
S19W SNP in the Apo11q gene cluster with premature
CAD as well as with lipids and lipoproteins in a cohort of
affected siblings belonging to Asian Indian families with
strong history of CAD. Additionally, we have attempted to
elucidate the relationship between circulating lipids and
conventional coronary risk factors in our cohort.
Methods
Study participants
A total of 523 families comprising 2318 individuals were
enrolled in Phase1 of the Indian Atherosclerosis Research
Study [IARS], an ongoing genetic epidemiological study
that aims to identify specific genes and regulatory path-
ways associated with CAD in the Asian Indian population.
Families were identified through a proband with a strong
family history of CAD and/or stroke, from select hospi-
tals/clinics in Bangalore and Mumbai. Probands were
defined as patients with angiographically proven ischemic
heart disease with age at onset ≤ 60 years for men and ≤
65 years for women. Other affected/unaffected family
members (parents, siblings, spouse and offspring over 18
years of age) were recruited when available and willing.
None of the participants had a history of past major ill-
ness or concomitant infection. The institutional ethics
committee approved the IARS, which was conceived
according to the guidelines defined by the Indian Council
of Medical Research for research conducted on human
subjects. A signed informed consent was obtained from all
participants in the study.
Questionnaire
A detailed case record form pertaining to information on
demographics, anthropometry, medical history and coro-
nary risk factors such as presence of diabetes, hyperten-
sion, smoking, lifestyle and current medication was
completed for each participant through personal inter-
views and through perusal of their medical records.
Blood sampling
Venous blood was collected in evacuated tubes after an
overnight fast of 12 to 14 hours (Vacuette®, Greiner Bio-
One GmbH, Vienna, Austria). Serum, EDTA and citrate
plasma samples were separated by centrifugation and
aliquots were preserved at -80°C until analysis. Cell pel-
lets were stored at -20°C and used for extraction of
genomic DNA at a later date.
Laboratory investigations
Serum Total cholesterol (TC), Triglycerides (TG), Lipopro-
tein (a) (Randox Laboratories Ltd, UK), High Density
Lipoprotein-cholesterol (HDL-cholesterol) (Bayer Diag-
nostics, Randox Laboratories, Dade-Behring Ltd, UK),
Apolipoprotein A1 (Apo A1) and Apolipoprotein B100
(Apo B) (Orion Diagnostics, Finland) were estimated on
the Cobas Fara II Clinical Chemistry Auto analyzer (F.Lipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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Hoffman La Roche Ltd., Switzerland), following the man-
ufacturer instructions. Serum Low Density Lipoprotein-
cholesterol (LDL-cholesterol) was calculated using the
Friedwald's formula. Three commercial controls pur-
chased from Randox Laboratories, one from Orion Diag-
nostica for apolipoproteins and a normal in-house serum
pool were run with every batch of assay. The inter-assay
coefficients of variation (CV) for the commercial controls
and normal serum pool ranged from 4.9% to 7.0% for TC,
6.1% to 7.7% for TG, 7.1% to 12.2% for HDL-cholesterol,
9.9% to 14.2% for ApoA1 and 10.7% to 13.9% for ApoB
levels.
Heritability of lipid traits
Heritability refers to the proportion of phenotypic vari-
ance attributable to genetic variance. Heritability esti-
mates were performed for the various atherothrombotic
phenotypes in 508 IARS families consisting of 2305 indi-
viduals. Circulating levels of lipid markers were measured
in family units comprising proband, spouse and off-
spring. Age- and sex-adjusted heritability was estimated by
variance component analysis using the sequential oligo-
genic analysis routine (SOLAR) (SOLAR v 1.4.1) program.
Spouse pair correlations were determined to account for
the household effects.
Genetic studies on the APOA1-C3-A5 gene cluster
Genomic DNA was extracted by the salting-out procedure
[31]. Based on the published reports of a strong associa-
tion between the 3238 C>G Sac I SNP (rs5128) in the
3'UTR of the APOC3 gene and plasma TG levels, a prelim-
inary linkage study was conducted on 190ASPs. Subse-
quently, two promoter SNPs, -75G>A (rs1799837) and
+83C>T (rs5069) in the APOA1 gene and the S19W SNP
(rs3135506) in exon 2 of the APOA5 gene were also
selected for genotyping in this study. Details of PCR prim-
ers, annealing conditions and restriction enzyme diges-
tion have been described elsewhere [10,32,33]. In short,
the genomic regions encompassing the polymorphic sites
were PCR amplified using site-specific primers, restriction
digested with appropriate restriction enzymes at 37°C
overnight and the digests were resolved on 2% agarose gel
for the APOA1 (Figure. 1A) and the APOA5 SNPs (Figure.
1C) while the APOC3 genotypes were resolved by 6%
polyacrylamide gel electrophoresis (PAGE) (Figure. 1B).
The Gene amp PCR System 2700 (Applied Biosystems,
CA, USA) was used for PCR amplification and gels were
stained with ethidium bromide and visualized by ultravi-
olet trans-illuminator. Images capture and analysis was
performed on DOC-IT and Lab works-4 software (UVP
Ltd. Cambridge, UK), respectively. All genotypes were
checked three times independently using appropriate het-
erozygotes as positive controls.
Affected sibling pairs [ASPs]
The present study consisted of 194 ASPs selected from 131
IARS families. Of these, there were 114 families contain-
ing 1 ASP, 14 with 3 ASPs and two families with 6 ASPs,
respectively, while one family consisted of 15 ASPs. Tak-
ing into account the genotyping failures in some cases,
only data on 190 ASPs for whom genotyping was per-
formed for all the four SNPs, was used in the final analy-
sis.
Linkage analysis
Non-parametric linkage analysis was performed by the
ASP analysis method [34] to test for linkage between CAD
and the four SNPs across the Apo11q gene cluster.
For the preliminary study, linkage between the Sac1 SNP
and plasma TG levels was tested using the deviation in the
proportions of 0-, 1- or 2- alleles shared, identity by state
(IBS) between the 190 ASPs, against an expected distribu-
tion of 25%, 50% and 25%, respectively. Association of
the Sac1 genotypes with plasma TG levels was tested by
analysis of variance (data unpublished).
Three additional SNPs (ApoA1 -75G>A, +83C>T and the
APOA5, S19W) were used for the subsequent linkage
study. Appropriate input files for linkage analysis were
created with the MEGA2 program [35]. Multipoint and
single point linkage analysis was performed using MERLI-
Nall and MERLINpairs options under MERLIN [36] as well
as the LODPAL option in S.A.G.E v. 5.3.1 package. Signif-
icant linkage was assigned based on the criteria of
Kruglyak et al [37]: 0 = no linkage; 1 = suggestive linkage;
2 = significant linkage; 3 = highly significant linkage; and
4 = confirmed linkage. Linkage and mean proportion of
alleles shared (pi), identity by descent (IBD), was tested
for each of the markers across the sib pairs. A pi that was
greater than 0.50 was considered as significant. The
GENIBD program in SAGE was used to run IBD analysis.
Subset analysis
On the basis of the individual sign of LOD score obtained
from linkage results on the entire dataset (N = 287), fam-
ilies where all ASPs showed a positive LOD score (LOD
score ≥ 0) (N = 104) were selected for further analysis
[38]. Additionally, families were classified based on the
following characteristics i.e. families having at least one
affected sibling in an ASP with age of onset less than 45
years (N = 108) and 'hyper TG families' where one (N =
162) or both sibling pairs (N = 46) had TG values ≥160
mg/dL. Linkage and IBD allele sharing was individually
calculated for the whole dataset and the subset groups.
Quantitative trait loci [QTL] analysis
Analysis of QTL was performed on families with positive
sign of LOD score and 'hyper TG families' using the 'QTL'Lipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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option in MERLIN program. All lipid variables (TC, TG,
HDL-cholesterol, LDL-cholesterol, ApoA1 and ApoB)
were independently tested against the four markers for
evidence of linkage. Age, gender, smoking, diabetes,
hypertension and statin use were used as covariates.
Association studies- statistical methods
Routine statistical analysis was performed using the SPSS
v.15 (Statistical program for social sciences) package.
Mean and standard error of mean (SEM) were calculated
for the quantitative variables. Genotype frequencies were
determined by direct counting. Conformity to Hardy-
Weinberg equilibrium was determined by χ2 test (P  >
0.05). The major allele was referred to as 1 and the minor
allele as 2; the corresponding genotypes were assigned as
1 1, 1 2 or 2 2 for the homozygous normal, heterozygotes
and homozygous variants, respectively. Genetic variants
with the 2 2 genotypes, having a frequency of less than 10
(Apo A1 +83C>T and Apo AV S19W) were grouped with
the heterozygotes for analysis purpose. Haplotype fre-
quency was estimated using the DECIPHER program of
SAGE.
Correlations among the plasma lipids and lipoproteins
were tested using the Pearson's correlation coefficients
estimate. Student t-test or ANOVA and multivariate anal-
yses were used to test for association between the Apo11q
SNPs and plasma levels of lipids and lipoproteins before
and after adjusting for confounding factors such as age,
gender, BMI, smoking, presence of diabetes or hyperten-
sion and statin use. Step-wise linear regression analysis
was employed to understand the extent of contribution of
individual SNPs to the variation in plasma lipid and lipo-
protein levels. The non-parametric Kolmogorov-Smirnov
test was used as test of normality for the quantitative var-
iables and the values were subsequently log-transformed
Representative gels of the 4 SNPs in the APOA1-C3-A5 gene cluster Figure 1
Representative gels of the 4 SNPs in the APOA1-C3-A5 gene cluster.
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to normalize distribution. CAD severity was defined on
the basis of age at CAD onset, the number of diseased ves-
sels and the event score (1 = ischemic heart disease with
chest pain, 2 = stable angina, 3 = unstable angina/MI)
classified according to the clinician's diagnosis. The Chi-
square test was used to test for association between geno-
types and CAD severity. Other discrete variables such as
presence/absence of diabetes, hypertension and smoking
were also tested against the 4 Apo11q SNPs. Presence of
diabetes (Type 2 DM) and hypertension (HTN) was ascer-
tained based on self-report of physician's diagnosis and/
or use of prescription medications along with proof
obtained from their medical records. A nominal P value of
0.05 or less was considered as statistically significant.
Canonical correlation statistics
In order to determine the contribution of SNPs to the var-
iation in lipid markers in a cohort of subjects with prema-
ture CAD, a two-stage procedure was adopted comprising
of correspondence analysis in the first stage followed by
canonical correlations [39]. The 'R' statistical package was
used for this analysis. Correspondence analysis is an
exploratory, multi-dimensional scaling technique that is
applied to discrete variables, wherein the row and column
weightages are obtained for maximum discrimination in
the form of a contingency table of categorical data. Here,
the linear functions of the row effects would best differen-
tiate the columns and vice versa.
The set of discrete variables consisted of the four SNPs in
the Apo11q cluster, hypertension and diabetes. In the first
stage, these categorical data were subjected to correspond-
ence analysis in order to obtain the scores for each row
category represented by the individual subjects in the
CAD group that were derived as linear functions of the
column profiles characterized by the respective genotypes
for the 4 SNPs, hypertension and diabetes. These provide
the least square estimates obtained as a linear function,
which act as weightages of each individual.
In the second stage, Canonical correlation analysis was
performed between the quantitative variables namely the
lipid markers, body mass index (BMI) and waist hip ratio
(WHR) (Set 1 variables) and the coordinates derived by
correspondence analysis carried out in the 1st stage (Set 2
variables). Canonical correlation analysis is a multivariate
data analysis technique, which maximizes the correlations
between the linear functions of two sets of variables. Since
canonical correlations are best defined when both the sets
are continuous in nature, we adopted this two-stage pro-
cedure.
Results
A total of 531 families were recruited in the Phase 1 of the
IARS, of which 23 incomplete families were excluded
from analysis. Of these, 131 families having 190 ASPs
were selected for the present study. Gender-wise distribu-
tion of lipid profile, CAD severity and coronary risk fac-
tors among the affected siblings is shown in Table 1. There
were more males (84.7%) than female (15.3%). Although
the mean levels of lipid markers were higher among the
females than males, significant differences were observed
only for TG (P = 0.046) and ApoA1 (P = 0.013). Diabetes
(P = 0.006) and hypertension (P = 0.004) were signifi-
cantly higher among females (67.4%, 72.1%) when com-
pared to the corresponding proportions in males (44.9%,
48.2%). While 47.3% of males were smokers, there were
no female smokers in our cohort. Mean age of CAD onset
was 50.3 ± 8.4 years for males and 53 ± 8.8 years for
females. The number of diseased vessels and event score
showed similar distribution in both sexes. More than 93%
of females were postmenopausal but none of them were
receiving hormone replacement therapy. Over 62.6% of
males and 78.3% of females were on the lipid lowering
drug, statin, respectively.
Heritability of lipid traits
Significant heritability (P < 0.0001) was observed for TC
(h2 = 0.65 ± 0.06), TG (h2 = 0.53 ± 0.06), HDL-cholesterol
(h2 = 0.48 ± 0.06), LDL-cholesterol (h2 = 0.55 ± 0.07), Apo
A1 (h2 = 0.71 ± 0.04) and Apo B (h2 = 0.70 ± 0.05). There
was minimal spouse-pair correlation for most lipid traits
(r = 0.02 – 0.09; P > 0.05) except HDL-cholesterol, which
showed a higher correlation coefficient value (r = 0.26; P
< 0.001).
Linkage analysis of the Apo11q markers and CAD
Preliminary studies on the APOC3-Sac1 polymorphism
and plasma TG levels on 190 ASPs showed that the pro-
portion of 0-, 1- and 2-alleles shared IBS, between the
ASPs was 6.3%, 38.9% and 54.8%, respectively, which
deviated significantly from the expected proportion of
25%, 50% and 25% allele sharing (P < 0.0001), suggest-
ing tentative linkage of the Sac-1 locus with CAD (Figure
2A). Significant difference was observed in the mean TG
levels (137.61 ± 4.35 mg/dl, 151.77 ± 6.95 mg/dl and
172.33 ± 11.72 mg/dl) (P < 0.0001) across the APOC3-
Sac1 genotypes, namely S1S1, S1S2, and S2S2, respec-
tively (Figure 2B).
Based on the suggestive linkage of the APOC3-Sac1 locus
to CAD and the association of minor allele with plasma
TG levels, this study was subsequently extended to include
three additional SNPs in the Apo11q gene cluster. No evi-
dence of linkage was observed by both multipoint and
single point linkage analysis as well as by IBD analysis for
any of the 4 SNPs in the whole data set. However, linkage
analysis on a subset of 47 families with 77 ASPs showing
a positive LOD score sign (LOD ≥ 0), gave highly signifi-
cant LOD score of 7.42 (P < 0.001) by multipoint analysisLipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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for the CAD trait, which was confirmed using the LOD-
PAL program of SAGE. Single point analysis showed
strong evidence of linkage for the Sac 1 SNP (LOD score
4.49; P < 0.0001) and a suggestive evidence of linkage for
the -75G>A SNP (LOD score 2.77; P = 0.0002). The mean
proportion of alleles shared IBD was significant for the
Sac-1 (pi 0.59; P < 0.0001), -75G>A (pi 0.56; P < 0.0001)
and +85C>T (pi 0.52; P  = 0.0012) SNPs using the
GENIBD program of SAGE. (Table 2)
Ordered subset analysis performed on ASPs, who were
selected based on age at onset < 45 years and plasma TG
levels, did not show any evidence of linkage.
Quantitative trait loci analysis
The APOC3-Sac 1 SNP showed suggestive evidence of
linkage to TC (LOD score 1.42; P = 0.005), HDL-choles-
terol (LOD score 1.72; P = 0.002) and Apo B (LOD score
1.19; P = 0.010) only in families with positive LOD score
(Table 2).
When the various coronary risk factors as well as CAD
severity were compared between the group with positive
sign of LOD score (N = 104) and negative sign of LOD
score (N = 181), the mean levels of the various lipid mark-
ers were marginally higher among the former group than
the latter group. The difference was statistically significant
only for plasma ApoA1 (P = 0.024) levels. Other features
such as CAD severity, BMI, WHR, and frequency of Type 2
DM and HTN showed similar distribution across the two
groups (Data not shown).
SNPs in the Apo11q gene cluster
All the four SNPs in the Apo11q cluster were in Hardy
Weinberg equilibrium (P  > 0.05). The distribution of
minor allele frequencies (MAF) and genotypes across the
four SNPs is given in Table 3. While the Sac-1 (0.32), the
-75G>A (0.19) and the 85C>T (0.15) SNPs were highly
polymorphic, the S19W SNP exhibited a low MAF (0.03).
Haplotype analysis using the PHASE program in SAGE
showed that the haplotypes with a frequency greater than
0.10 for the four SNPs, -75G>A, +83 C>T, Sac-1 and S19W
were 1-1-1-1 (0.40), 1-1-2-1(0.32) and 2-1-1-1 (0.15),
respectively.
Genotype-phenotype analysis
Association between the Apo11q genotypes and quantita-
tive phenotypes were performed on the whole dataset of
Table 1: Distribution of the various phenotypic variables in males and females.
DESCRIPTIVES MALES (N = 243) FEMALES (N = 44)
(%) Mean ± SD (%) Mean ± SD
Age at recruitment 57.2 ± 8.7 57.82 ± 7.59
Body Mass Index (kg/m2) 25.63 ± 3.8 28.38 ± 5.4
Waist-Hip-Ratio 0.96 ± 0.05 0.87 ± 0.09
Diabetes 44.9 67.4
Hypertension 48.2 72.1
Smoking 47.3 -
Total cholesterol 156.73 ± 39.3 166.23 ± 36.72
Triglycerides 149.39 ± 75.3 150.59 ± 52.02
High Density lipoprotein 37.86 ± 9.49 39.91 ± 8.75
Low Density Lipoprotein 88.88 ± 33.29 96.17 ± 35.43
Apolipoprotein A1 1.12 ± 0.24 1.18 ± 0.18
Apolipoprotein B100 0.92 ± 0.26 0.93 ± 0.20
Age at onset of CAD 51.34 ± 8.6 53.64 ± 7.8
Event score
1 (Mild) 3.9 4.8
2 (Moderate) 27.6 28.6
3 (Severe) 68.4 66.7
No. of disease vessels
11 6 . 9 2 3 . 3
22 1 . 9 3 0 . 0
≥ 36 1 . 2 4 6 . 4
Statin therapy 62.6 78.3
Beta blockers 55.7 69.6
ACE inhibitors 32.8 41.3
Calcium Channel blockers 37.3 23.9
Hypoglycemic agents 32.8 36.9
CAD, coronary artery disease.Lipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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190 ASPs comprising of 287 CAD subjects. Significant
correlation was observed among the lipid and lipoprotein
biomarkers using the Pearson's correlation coefficient
estimates (Table 4). While correlations between TC, TG,
LDL-cholesterol, ApoA1 and ApoB (r = 0.16 – 0.92; P <
0.001) were positive, there was significant negative corre-
lation between the HDL-cholesterol and TG levels (r = -
0.22; P < 0.001). This trend was retained following covari-
ate adjustment for age, gender and BMI.
Multivariate analysis showed significant differences in the
mean TG levels across the Sac-1 genotype (P = 0.007),
with mean LDL-cholesterol levels across the -75G>A gen-
otypes (P = 0.043) and with ApoA1 levels across the S19W
genotypes (P = 0.026). Age was a common confounding
factor that showed significant interaction with the lipids
while gender and BMI did not make any significant
impact in this dataset.
Results from linear regression analysis showed that
APOC3-Sac1 SNP was the only significant contributory
genetic marker among the 4 SNPs and was able to account
for about 2.8% (P = 0.005) of the variation in plasma TG
levels. With regard to the effect of conventional risk fac-
tors on lipids, HTN contributed to the variation in TC, TG,
LDL-cholesterol, ApoA1 and ApoB levels (1.8% – 4.6%; P
< 0.05), while waist hip ratio (WHR) contributed to over
1.5% (P = 0.037) of variation in HDL-cholesterol levels.
Age was the other significant contributory factor to the
variation among the plasma lipids (1.5% – 5.1%; P  <
0.05).
A. Mean Plasma TG Levels (mg/dl) across the APOC3 Sac1 genotypes Figure 2
A. Mean Plasma TG Levels (mg/dl) across the APOC3 Sac1 genotypes. B. Proportion of mean alleles shared across 
the APOC3-Sac 1 genotypes.
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Table 2: Findings of linkage analysis.
Analysis Method Whole data
(ASPs = 190)
Subset Data (Positive LOD score families) (ASPs = 77)
Sac1 LOD score
(P value)
-75G>A +83C>T
Multipoint Linkage analysis NS 7.42 (<0.001)
Single Point Linkage NS 4.49 (<0.0001) 2.77 (0.0002) NS
IBD Pi
(P value)
NS Pi 0.59 (<0.0001) Pi 0.56 (<0.0001) Pi 0.52 (0.0012)
QTL NS TC 1.42 (0.005)
HDL-c 1.72 (0.002)
ApoB 1.19 (0.010)
NS NS
ASPs, Affected sib pairs; IBD, identity by descent; Pi, mean proportion of allele sharing; NS, Not significant, QTL, Quantitative trait loci.Lipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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Estimation of maximized correlations
The results of correspondence analysis performed on the
discrete variables namely the four SNPs, HTN and Type 2
DM indicated that the first three components accounted
for nearly 79% of the total variability (Table 5). Based on
standardized weightages, it was shown that the first com-
ponent was characterized by the Sac1 (0.346) and -75G>A
(0.308) SNPs, while the same two SNPs along with HTN
(0.217) characterized the second component. Thus, these
three traits were able to show maximum contribution to
the variability in this CAD affected cohort. Structured cor-
relation between these variables and their components
indicated that the Sac1 SNP (0.844), the -75G>A SNP
(0.639) and HTN (0.559) showed maximum contribu-
tion towards the first two components. Diabetes trait
(0.915) was a significant contributor (p = 0.03) to the
third component, which was able to extract around 18%
of the total variability in this data set (Table 5).
The output of the canonical correlation analysis carried
out between the Set1 variables comprising of the quanti-
tative lipid traits and the Set 2 variables represented by the
components of the Apo11q genotypes, HTN and Type 2
DM obtained by correspondence analysis are presented in
Table 6, 7 and Table 7. Based on the R-square values, TG
(0.081, p < 0.000), Apo B (0.079, p < 0.000) and TC
(0.054, p < 0.025) were able to significantly contribute up
to 21% towards the CAD trait. (Table 6). The standardized
regression co-efficient data indicated that component 1
and component 2, characterized by the Sac-1 SNP, the -75
G>A SNP and HTN, were significantly associated with TG
(0.154, p < 0.008) for the first component, TG (B = -0.147,
p < 0.011) and ApoB (B = – 0.194, p < 0.001) for the sec-
ond component while the component 3, characterized by
DM, was associated with the Waist Hip Ratio (B = 0.117,
p = 0.049) (Table 7). The regression coefficients between
TG and ApoB with component 2 were observed to be neg-
ative. This is because, while calculating the least square
estimates of weights of individual subjects by correspond-
ence analysis, the components usually carry a +/- sign. The
negative sign obtained while calculating the least square
estimate values for the regression coefficients may be
neglected, as they do not carry a physical implication. The
output of the canonical correlation analyzed between the
Set 1 variables and Set 2 variables are presented in Table
8. Here, the first two components accounted for up to
77% of the total variability (Table 8) and hence only these
results are presented. The structured correlation between
the lipid biomarkers and their components indicated that
TG (r = 0.787), Apo B (r = 0.714) and TC (r = 0.469) con-
tributed towards the first component, which accounted
for over 52% of the maximized correlation, while HDL-
cholesterol (R = 0.525) for the second component
accounted for over 25% of the maximized correlations
(Table 8). Like-wise, the structured correlation between
the lipid biomarkers and the linear component of the sec-
ond set of variables also indicated that the contributions
of TG (R = 0.279), Apo B (R = 0.253) and TC (R = 0.166)
were the three lipid biomarkers which were directly influ-
enced by Sac 1 SNP, the -75 G>A SNP and hypertension in
this cohort (Table 8).
Discussion
In the present study consisting of a cohort of affected sib-
ling pairs selected from Asian Indian families with a
strong history of premature CAD, the APOC3, Sac-1 and
the ApoA1, -75G>A SNPs along with hypertension were
the significant contributory factors to the CAD trait, prob-
ably mediated through their association with lipid and
lipoprotein traits, particularly TC, TG and Apo B.
Table 3: Minor allele frequency and genotype distribution across 
the four Apo11q SNPs.
SNP MAF GENOTYPE
1 1
n (%)
1 2
n (%)
2 2
n (%)
-75G>A (rs1799837) 0.19 182 (65) 79 (31) 13 (4)
+83C>T (rs5069) 0.15 249 (90) 27 (10)
Sac1 (rs5128) 0.32 132 (46) 111 (44) 32 (10)
S19W (rs3135506) 0.03 270 (94) 17 (6)
MAF, minor allele frequency; SNP, single nucleotide polymorphism.
Table 4: Correlation coefficients between the lipid variables
TC TG HDL-c LDL-c ApoA ApoB
r (P value) r (P value) r (P value) r (P value) r (P value) r (P value)
TC - 0.44 (<0.001) 0.21 (<0.001) 0.92 (<0.001) 0.40 (<0.001) 0.71 (<0.001)
TG 0.44 <0.001) - -0.22 (<0.001) 0.16 (0.007) 0.21 (<0.001) 0.53 (<0.001)
HDL-c 0.21 (<0.001) -0.22 (<0.001) - 0.05 (0.38) 0.39 (<0.001) -.020 (.76)
LDL-c 0.92 (<0.001) 0.16 (0.007) 0.05 (0.38) - 0.25 (<0.001) 0.61 (<0.001)
ApoA1 0.40 (<0.001) 0.21 (<0.001) 0.39 (<0.001) 0.25 (<0.001) - 0.55 (<0.001)
ApoB 0.71 (<0.001) 0.53 (<0.001) -0.02 (0.76) 0.61 (<0.001) 0.55 (<0.001) -
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, Body mass index; HDL-c, high density- cholesterol; LDL-c, low density lipoprotein-
cholesterol; TC, total cholesterol; TG, triglyceridesLipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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Additional evidence was obtained by linkage analysis in a
subset of 77 ASPs who were selected based on positive
sign of LOD score. Here, the Sac1 and the -75G>A SNPs
showed significantly high LOD scores, implying linkage
of these two loci to CAD as well as tentative linkage of the
Sac1 SNP to TC, HDL-cholesterol and ApoB by QTL anal-
ysis. ASPs have been effectively used in linkage study, in
families with cervical carcinoma, to identify several sus-
ceptible regions as well as a potential candidate gene
underlying one of the loci on chromosome 9q32 region
[40]. Despite a relatively low sample size (No. of ASPs =
278), the strength of their study was in the dense panel of
over 500 microsatellite markers undertaken for their
investigation.
In the present investigation, while tests of association
have shown significant link between some of the Apo11q
SNPs and lipid phenotypes in CAD siblings, the output
from linkage analysis should be treated with some reser-
vations, given the absence of linkage evidence in the
whole dataset comprising of 190 ASPs. Although subset
linkage analysis based on particular phenotypic traits such
as lowered age of CAD onset or high TG levels within fam-
ilies has been generally popular in linkage studies [41],
subset analysis based on positive LOD scores has been
previously tested in schizophrenic patients [38] wherein
they had shown that patients in the subset group exhib-
ited a relatively severe clinical phenotype, which partly
justified their selection criteria. In our study, however, no
significant differences either pertaining to CAD severity or
biomarker levels could be associated with the families
with positive LOD score. Also, no evidence of linkage was
observed in the other subsets analyzed such as age at onset
less than 45 years or high TG levels. This may be attributed
to the small size of ASPs and low number of SNPs geno-
typed in this study, which might have considerably
reduced the power to detect significant linkage. Hence,
validation on a larger number of sibling pairs is impera-
tive before drawing definitive conclusions from these pre-
liminary findings.
CAD is a complex, multifactor disease with strong interac-
tion between the genes and environment [42]. In order to
estimate the small contributions from individual genetic
variants such as the SNPs or phenotypic traits such as the
lipids towards the manifestation of a complex disorder
Table 5: Correspondence analysis for discrete variables.
Component1 Component 2 Component 3 Component 4 Component 5
Inertia 0.0407 0.0223 0.0185 0.0153 0.0069
Cumulative Proportion 0.3924 0.6074 0.7862 0.9336 1
Coordinates
Sac1 0.346 -0.142 -0.031 -0.027 0.016
-75G>A -0.308 -0.216 -0.03 -0.073 0.028
+ 83C>T -0.054 0.057 -0.077 0.274 0.082
S19W -0.039 0.017 -0.031 0.07 -0.208
HTN -0.016 0.217 -0.133 -0.136 0.026
Type 2 DM -0.011 0.081 0.278 -0.016 0.018
Structured correlation
Sac1 0.844 0.142 0.007 0.005 0.002
-75G>A 0.639 0.313 0.006 0.036 0.005
+ 83C>T 0.031 0.035 0.063 0.799 0.072
S19W 0.03 0.006 0.019 0.096 0.849
HTN 0.003 0.559 0.21 0.22 0.008
Type 2 DM 0.002 0.077 0.915 0.003 0.004
HTN – hypertension; DM – Type 2 Diabetes mellitus.
Table 6: Squared multiple correlations
Variables R-Square p value
BMI (kg/m2) 0.023 0.266
WHR 0.021 0.321
TC (mg/dl) 0.045 0.025
TG (mg/dl) 0.081 0.000
HDL-c (mg/dl) 0.027 0.172
LDL-c (mg/dl) 0.037 0.065
Apo A1 (g/l) 0.031 0.114
ApoB (g/l) 0.079 0.000
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, Body mass 
index; HDL-c, high density- cholesterol; LDL-c, low density 
lipoprotein-cholesterol; TC, total cholesterol; TG, triglyceridesLipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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Table 7: Standardized regression coefficients and their probability values.
BMI
r (p value)
WHR
r (p value)
TC
r (p value)
TG
r (p value)
HDL-c
r (p value)
LDL-c
r (p value)
Apo A1
r (p value)
ApoB
r (p value)
Component 1 -0.01 (0.097) -0.003 (0.96) 0.071 (0.231) 0.154 (0.008) -0.102 (0.085) 0.049 (0.403) -0.016 (0.784) 0.071 (0.224)
Component 2 0.059 (0.32) -0.048 (0.42) -0.099 (0.091) -0.147 (0.011) 0.022 (0.715) -0.063 (0.284) -0.106 (0.074) -0.194 (0.001)
Component 3 0.051 (0.40) 0.117 (0.05) -0.011 (0.848) 0.102 (0.077) -0.079 (0.184) -0.031 (0.603) 0.057 (0.335) -0.011 (0.848)
Component 4 -0.037 (0.54) 0.066 (0.27) 0.149 (0.011) 0.155 (0.008) -0.026 (0.661) 0.119 (0.045) 0.115 (0.052) 0.188 (0.001)
Component 5 -0.076 (0.20) 0.012 (0.837) -0.083 (0.158) -0.0003 (0.996) 0.097 (0.104) -0.122 (0.041) 0.055 (0.353) -0.003 (0.961)
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BMI, Body mass index; HDL-c, high density- cholesterol; LDL-c, low density lipoprotein-
cholesterol; TC, total cholesterol; TG, triglycerides.
Table 8: Findings of canonical correlation analysis.
Component 1 Component 2
Canonical Correlation* 0.355 (0.0001) 0.253 (0.164)
Cumulative Proportion 0.524 0.773
Table 7a. Standardized canonical coefficients for Set 1 Variables
BMI (kg/m2) -0.4370 -0.2783
WHR 0.3720 -0.0457
TC (mg/dl) -28.2070 -160.216
TG (mg/dl) 10.1196 53.7325
HDL-c (mg/dl) 6.6342 39.3671
LDL-c (mg/dl) 24.6045 139.0919
Apo A1 (g/l) 0.2284 -0.4109
Apo B (g/l) 0.2654 1.2400
Table 7b. Structured correlations between Set 1 variables and their canonical variables
BMI (kg/m2) -0.2682 -0.3134
WHR 0.2892 -0.1466
TC (mg/dl) 0.4695 -0.1716
TG (mg/dl) 0.7874 -0.1806
HDL-c (mg/dl -0.2487 0.5254
LDL-c (mg/dl) 0.3015 -0.2712
Apo A1 (g/l) 0.4125 0.1872
Apo B (g/l) 0.7138 0.1761
Table 7c. Structured correlations between Set 1 variables and the canonical variables of Set 2 variables
BMI (kg/m2) -0.0952 -0.0794
WHR 0.1027 -0.0371
TC (mg/dl) 0.1667 -0.0435
TG (mg/dl) 0.2795 -0.0457
HDL-c (mg/dl) -0.0883 0.1331
LDL-c (mg/dl) 0.1070 -0.0687
Apo A1 (g/l) 0.1464 0.0474
Apo B (g/l) 0.2534 0.0446
Set 1 Variables – BMI, WHR, TC, TG, HDL-c, LDL, ApoA1, ApoB; Set 2 variables – Components 1–5 obtained from correspondence Analysis; * p 
value for significance of canonical correlation coefficient provided in parenthesisLipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
Page 11 of 14
(page number not for citation purposes)
like CAD calls for the application of rigorous statistical
techniques. To this effect, we used two methods, namely
correspondence analysis and canonical correlations, to
analyze our data. While correspondence analysis groups
the discrete variables into components based on their
individuals weightage contributions and estimates the sig-
nificant factors that contribute to the variability in the
dataset, canonical correlations help to maximize the cor-
relations between the linear functions of 2 sets of variables
[39]. By correspondence analysis, we were able to show
that the Sac-1 and -75G>A SNPs along with HTN belong-
ing to the first two components were able to explain up to
62% of the variability among the 287 affected family
members. On the other hand, these SNPs also showed sig-
nificant association with TC, TG and ApoB traits. This
indicates that the Apo11q variants might play a role in
impacting CAD risk through their regulation of specific
lipid biomarkers. A similar viewpoint has been reported
by other investigators [43,44]. At this point it would be
worthwhile to recall that the same two genetic variants
and two of the lipid traits, TC and Apo B, showed signifi-
cant linkage in subset analysis in this study.
Elevated plasma levels of TG and dense LDL-cholesterol
particles along with low levels of HDL-cholesterol consti-
tute an atherogenic lipoprotein phenotype [45]. That the
genes in the Apo11q gene cluster is associated with lipid
and lipoprotein phenotypes is well documented through
family-based linkage studies [46] as well as genome-wide
association studies [47], although the APOA1-C3-A4
region was able to explain less than 1% of the variation in
the trait [47]. In the present study, of the 4 genetic mark-
ers, the APOC3-Sac1 SNP was the only variant that signif-
icantly contributed to about 2.8% of variation in plasma
TG levels. The other SNPs, namely the -75G>A and the
+83C>T SNPs, were significantly associated with plasma
LDL-cholesterol and ApoA1 levels by multivariate analysis
in our study. It has been previously shown that contribu-
tions from haplotypes rather than effects from single pol-
ymorphic variant within the cluster make a larger impact
on the variation in circulating lipid levels [12].
The APOC3 Sac-1 polymorphism has been associated
with CAD [4,21] and the Apo A1 -75G>A and the +83C>T
SNPs have been reported to be a risk marker for CAD and
MI among the Indian [27] and the Japanese subjects [48],
respectively. Both the ApoA1 promoter SNPs are reported
to be in strong linkage disequilibrium [22]. In the present
study, both the Sac1 SNP and -75G>A SNP, the minor
alleles in particular, showed significant association with
CAD by correspondence analysis; however the +83C>T
SNP with a very low MAF (0.03) did not add any signifi-
cant value to our data analysis and findings. A similar low
frequency of this allele has been previously reported
among Asian Indians [29].
Environmental factors contribute significantly to the vari-
ation in plasma lipids [14]. While the IARS heritability
data provided evidence for the strong influence of genetic
factors for all the lipid traits, presence of small yet signifi-
cant spouse-pair correlations reflected the effect of shared
environmental risk factors in the IARS cohort. This was
further confirmed through multivariate analysis, wherein,
hypertension was an important factor that contributed
between 1.8%–4.6%, of the variation in lipid levels. Fur-
ther, hypertension was also a prominent feature of com-
ponent 2 by correspondence analysis, contributing to over
22% of the variability in our dataset. In this regard, the
report of an association between TG and the Apo11q gene
cluster among hypertensive subjects from the BRIGHT
study using genome wide approach is noteworthy [49].
Over 18% of the variability was attributed to Component
3, which was characterized by diabetes. Both hypertension
and diabetes have been traditionally considered as impor-
tant risk factors for CAD, especially among the Asian Indi-
ans [30]. Interestingly, diabetes also showed significant
association with WHR based on standardized regression
coefficients statistics. While there is a strong link between
obesity and diabetes, the fact that WHR is a better marker
of obesity than BMI has been reported previously by us
[50] as well as others [51], particularly with reference to
Asian Indians.
Over 49 SNPs have been determined in the 150 kb region
spanning this gene cluster [52] and the number of variants
has considerably increased following the addition of the
APOA5 gene, 27 bp downstream to the Apo11q cluster
[1]. The associated haplotypes within this genetically rich
region constitute a highly informative genetic marker for
the lipid trait [4]. Given this information, our study sup-
ports the notion that, the plasma lipids and lipoproteins,
regulated partly by the genetic markers and their haplo-
types within the Apo11q gene cluster, could serve as inter-
mediary risk phenotypes that contribute to the
pathophysiology of coronary artery disease.
While there is sufficient evidence for the association of
genes in the Apo11q cluster with regard to circulating TG
level, a recent report of a novel TG locus in the 1p31-32
region in Caucasian families with premature CAD/MI [53]
strengthens the observation that triglyceride is an impor-
tant risk marker for CAD, whose regulation may be under
the genetic control of several chromosomal loci distrib-
uted across the genome. A large multiethnic study identi-
fied a variant, rs35136575 in another lipoprotein
regulating loci, the apolipoprotein (APO) E/C1/C4/C2
cluster on chromosome 19, that accounted for 1% of var-
iation in the LDL-cholesterol levels and exerted a pleio-
tropic, context-dependent effect on plasma lipoproteins
[54]. The above findings point towards the complex proc-
esses that govern the expression of the genes regulatingLipids in Health and Disease 2008, 7:33 http://www.lipidworld.com/content/7/1/33
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plasma lipid levels that may be under the joint influence
of both genetic and environmental factors.
The present study has some shortcomings. Firstly, the size
of our study population is small, which might not have
had the power to detect evidence of linkage in the entire
cohort of 190 ASPs. Secondly, only 4 markers were evalu-
ated in a region spanning a large genomic distance of
around 150 cM and is characterized by a dense array of
SNPs, thereby reducing the probability of detecting the
causal variant/s. Thirdly, association with other SNPs
namely the ApoA1, +83C>T or APOA5, S19W was not
observed probably due to a low MAF. Fourth, as previ-
ously mentioned, although the evidence from linkage
analysis is encouraging, conducting subset analysis based
only on siblings with positive sign of LOD score could
lend bias to the findings. Finally, we are dealing with lipid
traits whose levels are affected by statins. Over 65% of the
subjects were on statin medication in this study. Although
we have taken care to adjust for statin use in our analysis,
we do not have information on the baseline lipid levels of
these subjects to understand the proportion of cholesterol
lowering effect that statins have on the circulating lipid
levels.
On the other hand, there are several positive aspects to
this study. The present cohort was enrolled from well-
characterized families with a strong history of premature
MI, which provide better opportunities to identify under-
lying association between the genetic markers and pheno-
typic traits in such a predisposed group. The IARS has
shown strong heritability for plasma phenotypes, particu-
larly the triglycerides, which prompted us to look into the
Apo11q region. Our exploratory studies had initially
shown strong association of the Sac-1 SNP to TG and ten-
tative linkage to CAD by IBS analysis (data unpublished),
which prompted us to expand by including additional
markers in this region. Our hypothesis was strengthened
by the findings of linkage analysis, albeit in a subset of the
cohort. Application of sophisticated statistical analysis
tool such as canonical correlations assisted in identifying
and segregating the specific variables, namely the Sac1
SNP, -75G>A SNP and hypertension, that showed maxi-
mum contribution to the variability in our dataset of
affected sibling pairs. The present study is to our knowl-
edge, the first report to simultaneously look into the link-
age and association of at least 4 markers in the APOA1-
C3-A5 gene cluster among Asian Indians with premature
CAD. However, our findings will benefit from the
sequencing of this region in a small group of probands in
order to understand the genetic variability of this highly
heterogeneous chromosomal region in a population that
does not have a representation, as yet, in the HAPMAP
database. We plan to embark on this study in the near
future. Additionally, we hope to confirm these prelimi-
nary, yet interesting observations, on a larger cohort of
over 2000 CAD patients and age and gender- matched
controls.
In conclusion, the Sac 1 and the -75G>A SNPs could serve
as useful tools for the direct quantitative measure of vari-
ation in lipid and lipoprotein levels and an indirect assess-
ment of CAD risk among the Asian Indian population.
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